Diabetes Management

Diabetes Management in Primary Care Practice

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia resulting from defects in insulin secretion, insulin action, or both. For the Family Nurse Practitioner (FNP), effective diabetes management is essential to reduce microvascular and macrovascular complications, improve quality of life, and meet quality metrics. This section focuses on the outpatient primary care management of type 2 diabetes (T2DM), with key considerations for type 1 diabetes (T1DM) as appropriate. High-yield exam content includes guideline-directed medication selection, individualized glycemic targets, and monitoring for complications.[1][2]

Foundational Terminology for Diabetes Care

  • Glycemic Control: Measured by hemoglobin A1c (HbA1c), continuous glucose monitoring (CGM) metrics, and self-monitored blood glucose (SMBG).
  • Insulin Resistance: Reduced sensitivity of peripheral tissues (muscle, fat, liver) to insulin, hallmark of T2DM.
  • Beta-cell Dysfunction: Progressive loss of pancreatic insulin secretion capacity.
  • Hypoglycemia: Blood glucose <70 mg/dL; a critical safety event requiring prompt treatment.
  • Diabetes Self-Management Education and Support (DSMES): Core component of diabetes care, improving outcomes.[3]
  • Social Determinants of Health (SDOH): Non-medical factors (food insecurity, health literacy) that influence diabetes outcomes.

Glycemic Targets, Pharmacotherapy, and Insulin Regimens

Glycemic Targets and Monitoring

Individualized goals are set based on age, comorbidities, life expectancy, and hypoglycemia risk. General targets for nonpregnant adults with T2DM:[1][2]

  • HbA1c: <7% (53 mmol/mol) for most adults; less stringent (e.g., <8%) for those with history of severe hypoglycemia, limited life expectancy, or advanced complications.
  • Fasting/premeal glucose: 80–130 mg/dL.
  • Postprandial glucose: <180 mg/dL (1–2 hours after start of meal).
  • Time in Range (TIR): >70% of readings 70–180 mg/dL (CGM metric).

Pharmacologic Approach to T2DM

The American Diabetes Association (ADA) recommends a patient-centered approach incorporating cardiovascular, renal, and weight considerations. Stepwise algorithm:[1]

  1. First-line therapy: Metformin (unless contraindicated or not tolerated) along with lifestyle modification.
  2. Add-on therapy if HbA1c above target: Consider GLP-1 receptor agonist (preferred in patients with atherosclerotic cardiovascular disease [ASCVD], heart failure, or chronic kidney disease [CKD]) or SGLT2 inhibitor (preferred for ASCVD, heart failure, or CKD).
  3. Injection intensification: Add basal insulin (e.g., glargine, degludec) or a GLP-1 RA if not already used; then prandial insulin if needed.
  4. Other agents: DPP-4 inhibitors, thiazolidinediones, sulfonylureas, meglitinides — used as second- or third-line when comorbidities are absent or access is limited.

Insulin Regimens

  • Basal insulin: Once-daily long-acting (glargine, detemir, degludec); titrate to fasting glucose targets.
  • Bolus (prandial) insulin: Rapid-acting (lispro, aspart, glulisine) given before meals.
  • Premixed insulins: Fixed combinations; less flexible but require fewer injections.
  • Intensive (basal-bolus) therapy: Used in T1DM and advanced T2DM.

Recognizing Acute and Chronic Diabetes Presentations

  • Hyperglycemia: Polyuria, polydipsia, polyphagia, blurred vision, fatigue, unintentional weight loss (more common in T1DM).
  • Diabetic ketoacidosis (DKA): Nausea/vomiting, abdominal pain, Kussmaul respirations, fruity breath, altered mental status; primarily T1DM.
  • Hyperosmolar hyperglycemic state (HHS): Severe hyperglycemia (>600 mg/dL), profound dehydration, altered consciousness; seen in T2DM.
  • Chronic complications: Neuropathy (numbness, paresthesias), nephropathy (microalbuminuria), retinopathy (vision changes), peripheral artery disease (claudication, nonhealing ulcers).

Diagnostic Criteria and Patient Evaluation Strategies

Diagnostic Criteria

Any one of the following confirms diabetes:[1]

  • HbA1c ≥6.5% (48 mmol/mol).
  • Fasting plasma glucose (FPG) ≥126 mg/dL (7.0 mmol/L) after at least 8 hours of no caloric intake.
  • 2-hour plasma glucose ≥200 mg/dL (11.1 mmol/L) during a 75-g oral glucose tolerance test (OGTT).
  • Random plasma glucose ≥200 mg/dL in a patient with classic hyperglycemic symptoms.

If asymptomatic, confirm with repeat testing on a different day unless unequivocal hyperglycemia is present.

Initial and Follow-up Evaluation

  • History: Age at diagnosis, weight history, family history, cardiovascular risk factors, symptoms of complications, hypoglycemia history, diet, physical activity, medication adherence.
  • Physical exam: BMI, blood pressure, fundoscopic exam, foot exam (monofilament test, pulses, ulcers), skin inspection.
  • Laboratory: HbA1c (quarterly if not at target; twice yearly if stable), renal function (serum creatinine, eGFR, urine albumin-to-creatinine ratio), lipid panel, liver enzymes, thyroid function (if T1DM suspect).

Lifestyle Modifications and Comprehensive Disease Management

Lifestyle and Self-Management

  • Medical Nutrition Therapy (MNT): Emphasize whole foods, fiber, lean proteins; reduce refined carbohydrates and added sugars. Refer to registered dietitian.[3]
  • Physical Activity: At least 150 minutes of moderate-intensity aerobic exercise per week; resistance training 2–3 times/week.
  • DSMES: Refer at diagnosis, annually, at care transitions, and when complications arise.
  • Smoking cessation: Strongly counsel; increased cardiovascular risk in diabetes.

Comorbidity Management

  • Hypertension: Target <130/80 mmHg (ADA). First-line: ACE inhibitor or ARB, especially if urinary albumin present.[1]
  • Dyslipidemia: Statin therapy of moderate-to-high intensity in most patients with diabetes; LDL goal <100 mg/dL (<70 mg/dL if high-risk).
  • Aspirin therapy: 81 mg daily for secondary prevention; consider for primary prevention in those with high cardiovascular risk and low bleeding risk.

Vaccinations

  • Influenza: Annually.
  • COVID-19: Per current CDC schedule.
  • Hepatitis B: For adults aged 19–59; consider for aged 60+ with risk factors.
  • Pneumococcal: PCV15 or PCV20; PPSV23 as indicated.
  • Zoster (Shingrix): Two doses for immunocompetent adults aged ≥50.

Risk Management and Adverse Event Prevention

  • Hypoglycemia: Major barrier to glycemic control. Educate patient on signs (tremor, diaphoresis, confusion) and treatment: “Rule of 15” — consume 15 g fast-acting carbohydrate, recheck in 15 minutes, repeat if still <70 mg/dL. Prescribe glucagon for those using insulin or sulfonylureas.
  • Severe adverse effects of medications:
    • Metformin: Lactic acidosis risk (rare); avoid if eGFR <30 mL/min/1.73 m².
    • SGLT2 inhibitors: Euglycemic DKA, genital mycotic infections, volume depletion; hold before surgery or during illness.
    • GLP-1 RAs: Nausea, vomiting; monitor for pancreatitis; thyroid C-cell tumor warning (contraindicated if personal/family history of medullary thyroid carcinoma).
    • Insulin: Weight gain, injection site lipodystrophy, human error in dosing.
  • Diabetic foot ulcers: Annual comprehensive foot exam; patient education on daily self-inspection, proper footwear, and prompt reporting of injury.
  • Renal function monitoring: Annual urine albumin-to-creatinine ratio and eGFR; adjust medication doses (e.g., metformin, SGLT2 inhibitors).

Clinical Pearls for Board Exam Readiness

  • Know the ADA algorithm: Metformin first; then prioritize agents with cardiovascular/renal benefit (GLP-1 RA, SGLT2i) over older agents (sulfonylureas, TZDs).
  • HbA1c is not everything: Recognize that A1c can be falsely low (hemolytic anemia, recent transfusion) or high (iron deficiency, CKD). Use CGM or SMBG for confirmation.
  • Individualize targets: The phrase “less stringent A1c goals” is a common test item for elderly, frail, or hypoglycemia-prone patients.
  • Antihyperglycemic prior authorization: FNPs often navigate insurance; know which agents require step therapy.
  • Acute illness management: “Sick day rules” — never stop insulin, increase monitoring, stay hydrated, take SGLT2i off if severely ill.
  • Memory aid for SGLT2i & GLP-1 RA benefits: “Heart and kidney, weight we bless — SGLT2 and GLP-1 success.”
  • Foot exam documentation: Must include monofilament test, pulse palpation, and inspection — a frequent quality measure.
  • Know diagnostic criteria for prediabetes: FPG 100–125, 2-hr OGTT 140–199, or HbA1c 5.7–6.4%. This is high yield.

References

  1. American Diabetes Association. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1):S1–S313. https://doi.org/10.2337/dc24-SINT
  2. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022. A consensus report. Diabetes Care. 2022;45(11):2753–2786. https://doi.org/10.2337/dci22-0034
  3. Powers MA, Bardsley JK, Cypress M, et al. Diabetes self-management education and support in adults with type 2 diabetes: a consensus report. Diabetes Care. 2020;43(7):1636–1649. https://doi.org/10.2337/dci20-0023
  4. Centers for Disease Control and Prevention. Diabetes basics. Updated May 15, 2024. https://www.cdc.gov/diabetes/basics/index.html

Ready to test your knowledge?

Master the core responsibilities, scope of practice, and limitations for the Family Nurse Practitioner exam.

Start Practice Questions
Previous Topic Next Topic